Article

FDA Approves New Treatment for Relapsing Forms of Multiple Sclerosis

Author(s):

Zinbryta is a long-acting injection that is self-administered by the patient every month.

The FDA has approved daclizumab (Zinbryta) as a treatment for adults with relapsing forms of multiple sclerosis.

Zinbryta is a long-acting injection that is self-administered by the patient every month.

The FDA's approval was based on results from 2 clinical trials. In the first trial, Zinbryta was compared with Avonex in 1841 patients over the course of 144 weeks. Those who used Zinbryta had fewer clinical relapses.

The second trial looked at Zinbryta vs placebo in 412 patients for 52 weeks. Again, patients experienced fewer relapses while taking Zinbryta when compared with the other group.

“Zinbryta provides an additional choice to patients who may require a new option for treatment,” said Billy Dunn, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said in a press release.

The FDA noted that Zinbryta should generally be used only in patients who do not respond well to 2 or more multiple sclerosis drugs, since the newly approved drug can lead to liver injury and serious immune conditions. The treatment’s boxed warning discusses severe liver injury, as well as conditions like noninfectious colitis, skin reactions, and enlargement of the lymph nodes.

Zinbryta, which was co-developed by Biogen and AbbVie, is only available under the Risk Evaluation and Mitigation Strategy program.

Health care professionals should conduct blood tests to monitor patients’ liver function before taking the medication, monthly, and up to 6 months after the last dose.

Some of the most common adverse effects associated with Zinbryta include cold symptoms, upper respiratory tract infection, rash, influenza, and dermatitis. When compared with placebo, Zynbryta was linked with with depression, rash, and increased alanine aminotransferase.

Multiple sclerosis is a chronic autoimmune disease that impacts the central nervous system. It disrupts communication between the brain and other parts of the body. Episodes of worsening function, or relapses, may fall in between recovery periods.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Caregiver holding elderly man's hand -- Image credit: Chinnapong | stock.adobe.com
Health care worker looking at MRI scans of dementia -- Image credit: Atthapon | stock.adobe.com